The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients

Camps, Carlos; Jantus‐Lewintre, Eloísa; Cabrera, A.; Blasco, Ana; Sanmartín, Elena; Gallach, Sandra; Caballero, Cristina; Pozo, Nieves del; Rosell, Rafael; Guijarro, Ricardo; Sirera, Rafael

doi:10.1016/j.lungcan.2010.09.005

Cited by 44 publications

(33 citation statements)

References 31 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…KRAS mutations have been found to be related to poor prognosis in several types of malignant disease. In a multivariate analysis, a KRAS mutation in the plasma of patients with non-small-cell lung cancer, pancreatic cancer or colorectal cancer was shown to predict poor OS and a high risk of recurrence [94-96]. APC and TP53 aberrations were found to have high sensitivity and specificity in predicting disease relapse in colorectal cancer, breast cancer, lung cancer and oral squamous-cell carcinoma [97-99].…”

Section: Diagnosis and Prognosis Assessmentmentioning

confidence: 99%

Liquid Biopsy for Cancer: Circulating Tumor Cells, Circulating Free DNA or Exosomes?

Zhang¹,

Xia

et al. 2017

Cell Physiol Biochem

209

150

View full text Add to dashboard Cite

Precision medicine and personalized medicine are based on the development of biomarkers, and liquid biopsy has been reported to be able to detect biomarkers that carry information on tumor development and progression. Compared with traditional ‘solid biopsy’, which cannot always be performed to determine tumor dynamics, liquid biopsy has notable advantages in that it is a noninvasive modality that can provide diagnostic and prognostic information prior to treatment, during treatment and during progression. In this review, we describe the source, characteristics, technology for detection and current situation of circulating tumor cells, circulating free DNA and exosomes used for diagnosis, recurrence monitoring, prognosis assessment and medication planning.

show abstract

Section: Diagnosis and Prognosis Assessmentmentioning

confidence: 99%

Liquid Biopsy for Cancer: Circulating Tumor Cells, Circulating Free DNA or Exosomes?

Zhang¹,

Xia

et al. 2017

Cell Physiol Biochem

209

150

View full text Add to dashboard Cite

show abstract

“…The authors have suggested that the detection of plasma mutated KRAS could serve as an alternative to invasive tissue biopsy in establishing prognosis in these patients. However earlier study by Camps et al (2011) using the same technique (qPCR) to detect plasma mutated KRAS showed no significant relationship with overall survival and progression-free survival in patients with advance-stage NSCLC. The opposing outcome between these two studies might be due to methodological differences.…”

Section: Applicability Of Ctdna As a Prognostic Biomarkermentioning

confidence: 81%

“…The opposing outcome between these two studies might be due to methodological differences. Both of these used qPCR to detect mutation, but the earlier study by Camps et al (2011) targeted only two KRAS mutations in codon 12, while the later study interrogated six KRAS mutations in codon 12 thus resulting in increased detection of plasma mutated KRAS (17.5% compared to 8.8% in earlier study). However, the prognostic value and clinical utility of ctDNA in the context of a resectable tumour is very limited.…”

Section: Applicability Of Ctdna As a Prognostic Biomarkermentioning

confidence: 99%

Circulating tumour DNA: a minimally invasive biomarker for tumour detection and stratification

Surani

Poterlowicz

2016

British Journal of Pharmacy

View full text Add to dashboard Cite

“…Conversely, in a NSCLC metaanalysis data review of the literature revealed negative correlation of the prognostic impact of RAS mutations mainly in adenocarcinoma cases [89]. While the KRAS mutations in patients with a form of metastatic NSCLC, these patients showed no response to chemotherapy [90,91]. Nevertheless, the response to EGFR TKIs is negatively predicted through KRAS mutations [35,92,93].…”

Section: Krasmentioning

confidence: 99%

Challenges and Strategies in Precision Medicine for Non-Small-Cell Lung Cancer

Sacco

Al‐Akhrass²,

Wilson

2016

CPD

View full text Add to dashboard Cite

Lung cancer is the most common cause of cancer-related death worldwide, causing over 1.2 million deaths each year. Non-small-cell lung cancer (NSCLC) consists of a group of malignancies that are pathologically and molecularly diverse but that are all characterised by a poor prognosis. Survival rates for lung cancer patients have improved very slowly and only to a modest degree owing partly to poor funding for research into this malignancy and stigma associated with smoking, as well as relative chemo-resistance. However, in recent years, NSCLC has become an exemplar for precision medicine, mainly following development of drugs targeting the receptors of epidermal growth factor and anaplastic lymphoma kinase. While epidermal growth factor receptor and anaplastic lymphoma kinase inhibitors are only applicable to a minority of patients and benefits are almost invariably short-lived, current studies indicate that at least 50% of patients with NSCLC have a targetable mutation. With a growing armamentarium of inhibitors against these targets in development, there is a hope that a greater proportion of patients will benefit from precision medicine and that such benefits will be sustained. However, there remain significant challenges in the development of precision medicine in NSCLC. These include: identification and validation of new targets; ensuring biopsies are fit for purpose; tumour heterogeneity; requirements for serial tumour assessments; and not least cost. In this review, we will discuss the current status of precision medicine in NSCLC as well as how basic and translational research are paving the way towards overcoming the above challenges. In addition, we will pay attention to clinical

show abstract

The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients

Cited by 44 publications

References 31 publications

Liquid Biopsy for Cancer: Circulating Tumor Cells, Circulating Free DNA or Exosomes?

Liquid Biopsy for Cancer: Circulating Tumor Cells, Circulating Free DNA or Exosomes?

Circulating tumour DNA: a minimally invasive biomarker for tumour detection and stratification

Challenges and Strategies in Precision Medicine for Non-Small-Cell Lung Cancer

Contact Info

Product

Resources

About